There was no correlation between the rates at which the tumours were proliferating and cellular immune competence.
CELL MEDIATED IMMUNITY IN
CHILDHOOD TUMOURS, S. Kumar, Christie Hospital, Manchester.
Lymphocytotoxicity tests using the Hellstr6ms' technique were carried out to study cell mediated and humoral immunity in several histological types of childhood tumour. Tumour type specific lymphocyte reactivity was detected in most of these patients; lymphocytes from children Mwith renal tumours showed a significant cross reactivity. The degree of lymphocyte mediated tumour cell killing appeared to be independent of the stage of progression of the tumour. Sera from children with clinically active tumours blocked the lymphocytotoxicity.
A NEW LOOK AT THE EB VIRUS AND ONCOGENESIS, R. N. P. Sutton, Department of Microbiology, King's College Hospital Medical School, London.
The EB virus, a herpes-like DNA virus, has been associated with malignant disease (Burkitt's lymphoma, nasopharyngeal carcinoma) and with infectious mononucleosis and asymptomatic infections. Spiegelman and his colleagues (Proc. natn. Acad. Sci. U.S. A., 1973, 70, 5) have recently detected nucleic acid homologous with that of the RNA Rauscher murine leukaemia virus in Burkitt's lymphoma and nasopharyngeal carcinoma cells.
This apparent conflict may be resolved by the assumption that the temporary depression of cell mediated immunity which occurs with EB infection in infectious mononucleosis also occurs in asymptomatic infections and is the necessary stimulus which activates an otherwise dormant RNA virus genome.
Sixty-eight children with acute lymphoblastic leukaemia were tested for antibodies to commonly encountered viruses, including the EB virus; their antibody responses were normal, indicating intact humoral immunity. In the case of the EB virus, the antibody pattern in children tested during the first month of their leukaemic illness suggested that a high proportion had experienced infection with this virus. In view of the potential immunosuppressive properties of the EB virus, it is suggested that these findings mav be related to the leukaemogenic process. Chlorambucil has been used extensively for the treatment of chronic lymphoblastic leukaemia but the development of resistance to the drug has restricted its usefulness. An understanding of its mode of action when used in combination with other substances may lead to a wider application of the drug in cancer therapy. In recent years vitamin A and caffeine have been reported to enhance the anti-tumour effect of certain alkylating agents (Cohen and Carbone, J. natn. Cancer Inst., 1972, 48, 921; Cohen, J. natn. Cancer Inst., 1972, 48, 927) .
In view of these observations, we have investigated the combined effect of chlorambucil, vitamin A, caffeine and phenobarbitone on an established tumour cell line derived from a male rat breast. The viable cell counts in chlorambucil (Chl), Chl + phenobarbitone (Pb), Chl + Pb + caffeine (Caf) and Chl + Pb + Caf + vitamin A were 610%, 4400, 40% and 25% of the control counts respectively after 3 days, at which time these combinations had their greatest efficacy. In recent years it has been possible to obtain growth of human tumours in " immune deprived " rodents. We have observed that certain types of tumour, for example, carcinoma of the colon and rectum, almost invariably become established and others have proved difficult to grow. During this work a number of factors have emerged that seem likely to influence the establishment of human tumour grafts. These factors include species of recipient, method of immune deprivation, blood levels of sex hormones in the recipient and size and site of implant. Phenothiazines cause a rise in plasma prolactin in normal subjects when given orally or by injection (Frantz et al. and Bryant and Greenwood, 1972 . Ciba Symposium Lactogenic Hormones. Ed. G. B. W.
CHLORPROMAZINE
Wolstenholme and J. Knight. London and Edinburgh: Churchill Livingstone). Turkington (J. clin. Endocr. 1972, 34, 247) described the acute stimulation of prolactin secretion using 50 mg of chlorpromazine i.m. The prolactin response was diminished in hypopituitarism.
Six patients with breast cancer were similarly tested. The plasma prolactin response was measured by homologous radioimmunoassay. The mean basal plasma prolactin was 13-7 + (s.e.) 7-5 mAmp/ml. This rose to a peak of 77-3 ± 11-4 mAmp/ml within 2 hours of the injection.
One to three months after yttrium implant pituitary ablation for advanced breast cancer, patients received a similar stimulation of residual prolactin cell function. This was in addition to the standard test of growth hormone response to insulin reduced hypoglycaemia (Stewart et al., J. Endocr., 1971, 50, 41 
